表紙
市場調査レポート

MediPoint:生体吸収性ステント - 米国および欧州市場の分析と予測

MediPoint: Bioabsorbable Stents - Global Analysis and Market Forecasts

発行 GlobalData 商品コード 260974
出版日 ページ情報 英文 155 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
MediPoint:生体吸収性ステント - 米国および欧州市場の分析と予測 MediPoint: Bioabsorbable Stents - Global Analysis and Market Forecasts
出版日: 2012年12月31日 ページ情報: 英文 155 Pages
概要

冠動脈疾患と末梢動脈疾患は、毎年、世界で何百万もの生命に影響を及ぼす、公衆衛生および社会経済上の課題だといえます。体内の管を一時的にサポートし、時間とともに分解される生体吸収性ステントは、恒久的に管内に存在し続ける薬剤溶出ステントやベアメタルステントの有望な代替製品です。

当レポートでは、米国、フランス、ドイツ、イタリア、スペイン、英国における生体吸収性ステント(BAS)市場に関する詳細な分析を行っており、同市場における機会や障壁、主要動向、売上予測、競合状況、開発中のパイプライン製品などの情報を、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 調査の動機
  • 関連レポート

第3章 疾患の概要

  • 冠動脈疾患(CAD)
  • 末梢動脈疾患(PAD)
  • 解剖生理学
  • 病態生理
    • 冠動脈疾患(CAD)
    • 末梢動脈疾患(PAD)
  • 臨床所見
    • 冠動脈疾患(CAD)の症状
    • 末梢動脈疾患(PAD)の症状
    • リスク因子
    • 疾患区分
    • 診断
  • 臨床転帰
    • 治療パラダイム
    • 治療モダリティ
    • 冠動脈/末梢動脈バイパス手術
    • 心血管インターベンション
  • 疫学
    • 冠動脈疾患(CAD)
    • 末梢動脈疾患(PAD)
  • 経済的影響
    • 冠動脈疾患(CAD)
    • 末梢動脈疾患(PAD)
    • 治療費

第4章 競合評価

  • 概要
  • Absorb BVS - Abbott Vascular
  • Remedy - 京都医療設計

第5章 アンメットニーズ

  • 生体分解性および生体吸収性ステント
  • 合併症リスクの低減
  • Stent-in-Stent処置の必要性の削減
  • 長期臨床データ
  • ステント破損
  • 抗血小板薬の2剤併用療法(DAPT)
  • イメージング

第6章 パイプライン製品

  • 概要
  • 開発段階別のパイプライン - 冠動脈疾患(CAD)
  • パイプライン製品のプロファイル - 冠動脈疾患(CAD)
  • 開発段階別のパイプライン - 末梢動脈疾患(PAD)
  • パイプライン製品のプロファイル- 末梢動脈疾患(PAD)
  • 治験の分析

第7章 産業の概要

  • 処置動向
  • 市場アクセス
    • 米国
    • 欧州
  • 償還動向
    • 米国
    • 欧州
  • 規制上の課題/リコール

第8章 現在のプレーヤーと将来有望なプレーヤー

  • 概要
  • 企業戦略における動向
  • 企業プロファイル

第9章 市場発展因子・機会・障壁

  • 市場発展因子
  • 機会
  • 市場障壁

第10章 国別の見通しと予測

  • 主要6市場の概要
  • 米国
    • 概要
    • 市場分析
  • フランス
    • 概要
    • 市場分析
  • ドイツ
    • 概要
    • 市場分析
  • イタリア
    • 概要
    • 市場分析
  • スペイン
    • 概要
    • 市場分析
  • 英国
    • 概要
    • 市場分析

第11章 付録

目次
Product Code: GDME0164MAR

Summary

Coronary artery disease and peripheral artery disease are global public health and socioeconomic issues that affect millions of lives each year. Bioabsorbable stents, which provide transient support to the vessel and degrade overtime, are viable alternatives to permanent drug-eluting and bare metal stent implants. In the report, bioabsorbable stents are defined as fully biodegradable stents that completely disappear over time. The emerging Bioabsorbable Stent (BAS) market is steadily growing in the major markets in Europe (France, Germany, Italy, Spain and the UK), dominated by Abbott Vascular and Kyoto Medical Planning, with new entrants including Biotronik, REVA Medical and Elixir Medical Corporation. In the US, bioabsorbable stents have not received regulatory approval and are not available for sale. By the end of our forecast period, the competitive landscape will experience significant change due to the launch of BAS products in the US, the expansion of approved indications to include patients with more complex forms of coronary and peripheral artery disease and the entry of new companies such as OrbusNeich and Arterial Remodelling Technologies by 2018. This report is built using data and information sourced from secondary sources and primary research interviews with leading Interventional Cardiologists, Cardiovascular Surgeons and Interventional Radiologists with in-house analysis conducted by GlobalData's team of industry experts.

Scope

  • Overview of coronary and peripheral artery disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized Bioabsorbable Stent market revenue, annual cost of disease and BAS adoption pattern data from 2009-2011 and forecast for seven years to 2018.
  • Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement considerations, and implications for the BAS market.
  • Pipeline analysis: comprehensive data split across different stages of development, emerging trends and mechanisms of implantation under development, including investigation of repositionability, device size, expansion mechanism, valve conformance, durability and material selection.
  • Analysis of the current and future market competition in the global BAS market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global BAS market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BAS market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global BAS market from 2009-2018.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Coronary Artery Disease
  • 3.2. Peripheral Artery Disease
  • 3.3. Anatomy and Physiology
  • 3.4. Pathophysiology
    • 3.4.1. Coronary Artery Disease
    • 3.4.2. Peripheral Artery Disease
  • 3.5. Clinical Presentation
    • 3.5.1. Symptoms of Coronary Artery Disease (NHLBI, 2011c)
    • 3.5.2. Symptoms of Peripheral Artery Disease (Stoppler, 2012)
    • 3.5.3. Risk Factors
    • 3.5.4. Disease Segments
    • 3.5.5. Diagnosis
  • 3.6. Clinical Outcomes
    • 3.6.1. Treatment Paradigm
    • 3.6.2. Treatment Modalities
    • 3.6.3. Coronary/Peripheral Artery Bypass Grafting
    • 3.6.4. Interventional Cardiology
  • 3.7. Epidemiology
    • 3.7.1. Coronary Artery Disease
    • 3.7.2. Peripheral Artery Disease
  • 3.8. Economic Impact
    • 3.8.1. Coronary Artery Disease
    • 3.8.2. Peripheral Artery Disease
    • 3.8.3. Treatment Costs

4. Competitive Assessment

  • 4.1. Overview
  • 4.2. Absorb BVS - Abbott Vascular
    • 4.2.1. Efficacy
    • 4.2.2. SWOT Analysis
  • 4.3. Remedy - Kyoto Medical Planning
    • 4.3.1. Efficacy
    • 4.3.2 SWOT Analysis

5. Unmet Needs

  • 5.1. Biodegradable and Bioabsorbable Stents
  • 5.2. Reduce Risk of Complications
  • 5.3. Reduce the Need for Stent-in-Stent Procedures
  • 5.4. Long-Term Clinical Data
  • 5.5. Stent Fracture
  • 5.6. Dual Anti-Platelet Therapy
  • 5.7. Imaging

6. Pipeline Products

  • 6.1. Overview
  • 6.2. Pipeline by Phases in Development - Coronary Artery Disease
  • 6.3. Pipeline Product Profiles - Coronary Artery Disease
    • 6.3.1. Igaki-Tamai Stent
    • 6.3.2. ReZolve Sirolimus Eluting Bioabsorbable Coronary Scaffold
    • 6.3.3. Drug-Eluting Absorbable Metal Scaffold
    • 6.3.4. Absorbable Metal Stents
    • 6.3.5. DESolve Bioabsorbable Coronary Scaffold System
    • 6.3.6. ART Stent
    • 6.3.7. The OrbusNeich Stent
    • 6.3.8. TephaFLEX Absorbable Stent
    • 6.3.9. The Arterius Stent
    • 6.3.10. Zorion Medical Stent
    • 6.3.11. 3V Avatar
    • 6.3.12. Biosorb
    • 6.3.13. Summary
  • 6.4. Pipeline by Phases in Development - Peripheral Artery Disease
  • 6.5. Pipeline Product Profiles- Peripheral Artery Disease
    • 6.5.1. Magic Explorer Stent
    • 6.5.2. Esprit Bioabsorbable Vascular Scaffold
    • 6.5.3. ART Stent
    • 6.5.4. TephaFLEX Absorbable Peripheral Stent
    • 6.5.5. Zorion Medical Stent
    • 6.5.6. Amaranth Medical Stent
    • 6.5.7. Summary
  • 6.6. Clinical Trial Analysis
    • 6.6.1. Overview
    • 6.6.2. Trials to Watch

7. Industry Overview

  • 7.1. Procedure Trends
    • 7.1.1. Factors Contributing to Rise of Coronary and Peripheral Interventions
    • 7.1.2. Coronary Artery Disease
    • 7.1.3. Peripheral Artery Disease
  • 7.2. Market Access
    • 7.2.1. United States
    • 7.2.2. Europe
  • 7.3. Reimbursement Trends
    • 7.3.1. United States
    • 7.3.2. Europe
  • 7.4. Regulatory Issues/Recalls

8. Current and Future Players

  • 8.1. Overview
  • 8.2. Trends in Corporate Strategy
  • 8.3. Company Profiles
    • 8.3.1. Abbott Vascular
    • 8.3.2. Kyoto Medical Planning Co., Ltd
    • 8.3.3. Biotronik SE & Co. KG
    • 8.3.4. REVA Medical, Inc.
    • 8.3.5. Elixir Medical Corporation
    • 8.3.6. Arterial Remodeling Technologies
    • 8.3.7. Tepha, Inc.
    • 8.3.8. OrbusNeich
    • 8.3.9. Arterius
    • 8.3.10. Zorion Medical
    • 8.3.11. S3V Vascular Technologies
    • 8.3.12. ICON Interventional Systems
    • 8.3.13. Amaranth Medical
    • 8.3.14. Medlogics Device Corporation

9. Market Drivers, Opportunities and Barriers

  • 9.1. Market Drivers
    • 9.1.1. Rising Prevalence of Disease
    • 9.1.2. Avoid Stent-in-Stent Procedures
    • 9.1.3. Reduce/Eliminate Dual Anti-Platelet Therapy
    • 9.1.4. Availability of Long-Term Data
    • 9.1.5. Treatment Cost Considerations
    • 9.1.6. Accurate Stent Placement
    • 9.1.7. Expected Launch of Bioabsorbable Stents in the US
  • 9.2. Opportunities
    • 9.2.1. Bioabsorbable Stent Market Segmentation
    • 9.2.2. Expand Indications of Bioabsorbable Stenting
    • 9.2.3. Target High-Risk Patients
    • 9.2.4. Improve Deliverability of Bioabsorbable Stents
    • 9.2.5. Emerging Markets
  • 9.3. Market Barriers
    • 9.3.1. Slow Adoption
    • 9.3.2. Complications with Bioabsorbable Stents
    • 9.3.3. High Selling Price
    • 9.3.4. Reimbursement
    • 9.3.5. Substitutes

10. Country Outlooks and Forecasts

  • 10.1. Six Major Markets Overview
  • 10.2. United States
    • 10.2.1. Overview
    • 10.2.2. Market Analysis
  • 10.3. France
    • 10.3.1. Overview
    • 10.3.2. Market Analysis
  • 10.4. Germany
    • 10.4.1. Overview
    • 10.4.2. Market Analysis
  • 10.5. Italy
    • 10.5.1. Overview
    • 10.5.2. Market Analysis
  • 10.6. Spain
    • 10.6.1. Overview
    • 10.6.2. Market Analysis
  • 10.7. United Kingdom
    • 10.7.1. Overview
    • 10.7.2. Market Analysis

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Report Methodology
    • 11.3.1. Overview
    • 11.3.2. Coverage
    • 11.3.3. Secondary Research
    • 11.3.4. Forecasting Methodology
  • 11.4. Physicians and Specialists Included in this Study
  • 11.5. Physician Survey
  • 11.6. About the Authors
    • 11.6.1. Analysts
    • 11.6.2. Global Head of Healthcare
  • 11.7. About MediPoint
  • 11.8. About GlobalData
  • 11.9. Contact Us
  • 11.10. Disclaimer

List of Tables

  • Table 1: Risk Factors Associated with Coronary Artery Disease
  • Table 2: Risk Factors Associated with Peripheral Artery Disease
  • Table 3: Types of Coronary Artery Bypass Grafting
  • Table 4: Drugs Incorporated into Drug-Eluting Stents
  • Table 5: Total Prevalence of CAD in +65 population in the Major Markets, millions
  • Table 6: Total Prevalence of PAD Among +65 Population in the Major Markets, millions
  • Table 7: Description of Direct and Indirect Economic Costs
  • Table 8: Economic Impact ($bn) of CAD in the Major Markets
  • Table 9: Economic Impact ($bn) of PAD in the Major Markets*
  • Table 10: US Hospital Charges for Interventional Cardiology Procedures
  • Table 11: Marketed Bioabsorbable Stent Products
  • Table 12: Absorb BVS Product Portfolio
  • Table 13: Absorb BVS SWOT Analysis, 2012
  • Table 14: Remedy Stent Product Portfolio
  • Table 15: Remedy SWOT Analysis, 2012
  • Table 16: BAS Global Product Pipeline (Coronary)
  • Table 17: Igaki-Tamai Stent SWOT Analysis, 2012
  • Table 18: ReZolve Stent SWOT Analysis, 2012
  • Table 19: DREAMS SWOT Analysis, 2012
  • Table 20: AMS SWOT Analysis, 2012
  • Table 21: BAS Global Product Pipeline (Peripheral)
  • Table 22: Magic Explorer Stent SWOT Analysis, 2012
  • Table 23: Esprit BVS SWOT Analysis, 2012
  • Table 24: Medicare National Average of Inpatient Hospital Payment for Cardiology Procedures, 2011-2012
  • Table 25: Company Profile - Abbott Vascular
  • Table 26: Marketed Bioabsorbable Stent Products by Abbott Vascular
  • Table 27: Pipeline Bioabsorbable Stent Products by Abbott Vascular
  • Table 28: Abbott Vascular SWOT Analysis, 2012
  • Table 29: Company Profile - Kyoto Medical Planning
  • Table 30: Marketed Bioabsorbable Stent Products by Kyoto Medical Planning
  • Table 31: Pipeline Bioabsorbable Stent Products by Kyoto Medical Planning
  • Table 32: Kyoto Medical Planning SWOT Analysis, 2012
  • Table 33: Company Profile - Biotronik
  • Table 34: Pipeline Bioabsorbable Stent Products by Biotronik
  • Table 35: Biotronik SWOT Analysis, 2012
  • Table 36: Company Profile - REVA Medical
  • Table 37: Pipeline Bioabsorbable Stent Products by REVA Medical
  • Table 38: REVA Medical SWOT Analysis, 2012
  • Table 39: Company Profile - Elixir Medical Corporation
  • Table 40: Pipeline Bioabsorbable Stent Products by Elixir Medical Corporation
  • Table 41: Elixir Medical Corporation SWOT Analysis, 2012
  • Table 42: Company Profile - Arterial Remodeling Technologies
  • Table 43: Pipeline Bioabsorbable Stent Products by Arterial Remodeling Technologies
  • Table 44: Arterial Remodeling Technologies SWOT Analysis, 2012
  • Table 45: Company Profile - Tepha
  • Table 46: Pipeline Stent Products by Tepha
  • Table 47: Tepha SWOT Analysis, 2012
  • Table 48: Company Profile - OrbusNeich
  • Table 49: Pipeline Bioabsorbable Stent Products by OrbusNeich
  • Table 50: OrbusNeich SWOT Analysis, 2012
  • Table 51: Company Profile - Arterius
  • Table 52: Arterius SWOT Analysis, 2012
  • Table 53: Company Profile - Zorion Medical
  • Table 54: Zorion Medical SWOT Analysis, 2012
  • Table 55: Company Profile - S3V Vascular Technologies
  • Table 56: S3V Vascular Technologies SWOT Analysis, 2012
  • Table 57: Company Profile - ICON Interventional Systems
  • Table 58: ICON Interventional Systems SWOT Analysis, 2012
  • Table 59: Company Profile - Amaranth Medical
  • Table 60: Amaranth Medical SWOT Analysis, 2012
  • Table 61: Company Profile - Medlogics Device Corporation
  • Table 62: Medlogics Device Corporation SWOT Analysis, 2012
  • Table 63: Global Sales ($m) Forecast for Bioabsorbable Stents, 2011-2018
  • Table 64: Bioabsorbable Stent Sales ($m) Forecast for the United States, 2011-2018
  • Table 65: Bioabsorbable Stent Sales ($m) Forecast in France, 2011-2018
  • Table 66: Bioabsorbable Stent Sales ($m) Forecast in Germany, 2011-2018
  • Table 67: Bioabsorbable Stent Sales ($m) Forecast in Italy, 2011-2018
  • Table 68: Bioabsorbable Stent Sales ($m) Forecast in Spain, 2011-2018
  • Table 69: Bioabsorbable Stent Sales ($m) Forecast for United Kingdom, 2011-2018
  • Table 70: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Anatomy of the Human Heart
  • Figure 2: Pathophysiology of Coronary Artery Disease
  • Figure 3: Pathophysiology of Peripheral Artery Disease
  • Figure 4: Treatment Modalities - Coronary Artery Disease
  • Figure 5: Interventional Cardiology Procedures for Treating CAD, US and Europe, 2012
  • Figure 6: Treatment Modalities - Peripheral Artery Disease
  • Figure 7: Interventional Cardiology for Treating PAD, US and Europe, 2012
  • Figure 8: Types of Stents
  • Figure 9: Global Prevalence of CAD in Population ≥65 Years, millions
  • Figure 10: Percent of Patients (≥65 years) Treated for CAD, US and Europe
  • Figure 11: Global Prevalence of PAD in Population ≥65 Years, 2011-2018
  • Figure 12: Direct and Indirect Costs ($bn) of CAD in the Major Markets
  • Figure 13: Total Costs ($bn) of PAD in the Major Markets
  • Figure 14: US Hospital Charges for Interventional Procedures, 2011-2018
  • Figure 15: Importance of a Biodegradable and Absorbable Stent to Physicians in the US and Europe (n=50)
  • Figure 16: Percent of Patients with CAD Patients Experiencing Complications after Drug-Eluting Stenting, 2012 (n=25)
  • Figure 17: Percent of Patients with PAD Patients Experiencing Complications after Drug-Eluting Stenting, 2012 (n=25)
  • Figure 18: Percent of Patients (≥ 65 years) with CAD Receiving Stent-in-Stent Procedures, 2012 (n=25)
  • Figure 19: BAS Coronary Pipeline by Stage in Clinical Development, 2012
  • Figure 20: BAS Peripheral Pipeline by Stage in Clinical Development, 2012
  • Figure 21: Population (≥ 65 years) of CAD Patients Receiving Interventional Procedures in the US
  • Figure 22: Population (≥ 65 years) with CAD Receiving Interventional Procedures in Europe*
  • Figure 23: Population (≥ 65 years) of PAD Patients Receiving Interventional Procedures in the US
  • Figure 24: Population (≥ 65 years) with PAD Receiving Interventional Procedures in Europe*
  • Figure 25: Likelihood of Physicians Adopting Bioabsorbable Stents in the United States and Europe, 2012 (n=50)
  • Figure 26: Medicare National Average of Outpatient Hospitalization Payment for Interventional Cardiology Procedures, 2011-2012
  • Figure 27: National Medicare Average Payment for Drug-Eluting Stent Procedures for the Following Years
  • Figure 28: Kyoto Medical Planning Co., Ltd. Sales Volume ($m), May 2002-May 2012
  • Figure 29: Global Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 30: Bioabsorbable Stents Total Revenue
  • Figure 31: US Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 32: French Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 33: German Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 34: Italian Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 35: Spanish Bioabsorbable Stent Market ($m), 2011-2018
  • Figure 36: UK Bioabsorbable Stent Market ($m), 2011-2018
Back to Top